Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats

Behavioural Brain Research

Volumn 136, Issue 1, 2002, Pages 317-324

  Alam, M ^a   Schmidt, W J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Complex I; Dopamine; Mitochondria; NADH dehydrogenase; Parkinson's; Rotenone; Substantia nigra; Tyrosine hydroxylase

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; HOMOVANILLIC ACID; ROTENONE; TYROSINE 3 MONOOXYGENASE;

ANIMAL BEHAVIOR; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALEPSY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; FEMALE; IMMUNOREACTIVITY; NERVE DEGENERATION; NONHUMAN; OPEN FIELD TEST; PARKINSONISM; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SYMPTOM;

ANIMALS; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; CATALEPSY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; ELECTROCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; NEOSTRIATUM; NEURONS; PARKINSON DISEASE, SECONDARY; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; ROTENONE; TYROSINE 3-MONOOXYGENASE; UNCOUPLING AGENTS;

EID: 0037126181     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(02)00180-8     Document Type: Article

References (11)

1. Betarbet R., Sherer T.B., MacKenzie Gillian, Garcia-Osuna M.V., Panov A., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neurosci. 3:2000;1301-1306.
2. Ellenbroek B.A., Cools A.R. Animal models with construct validity for schizophrenia. Behav. Pharmacol. 1:1990;469-490.
3. Erecinska M., Nelson D., Deas J., Silver I.A. Metabolic and energetic properties of isolated nerve ending particles (synaptosomes). Biochim. Biophys. Acta. 1277:1996;13-34.
4. Fearnley J.M., Lee A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 14:1991;2283-2301.
5. Ferrante R.J., Schulz J.B., Kowall, Beal M.F. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res. 753:1997;157-162.
6. Heffner T.G., Hartmann J.A., Seiden L.S. A rapid method for the regional dissection of brain. Pharmacol. Biochem. Behav. 13:1980;453-456.
7. Marey Semper I., Gelman M., Levi Strauss M. A selective toxicity toward cultured mesencephalic dopaminergic neurons is induced by the synergistic effects of energetic metabolism impairment and NMDA receptor activation. J. Neurosci. 15:1995;5912-5918.
8. Mizuno Y., Hattori N., Matsumine H. Neurochemical and neurogenetic correlates of Parkinson's disease. J. Neurochem. 71:1998;1864-1869.
9. Schapira A.H. Mitochondrial function and neurotoxicity. Curr. Opin. Neurol. 7:(6):1994;531-536.
10. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54:1990;823-827.
11. Schmidt W.J., Kretschmer B.D. Behavioural pharmacology of glutamate receptors in the basal ganglia. Neurosci. Biobehav. Rev. 21:(4):1997;381-392.